Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Orrey Padilla
- Phone Number: 305-243-1491
- Email: oxp210@med.miami.edu
Study Contact Backup
- Name: Odaro Ugbo, BSc
- Phone Number: 305-243-1491
- Email: oxu32@miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Principal Investigator:
- Emad Ibrahim, MD
-
Contact:
- Orrey Padilla
- Phone Number: 305-243-1491
- Email: oxp210@med.miami.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject has a traumatic spinal cord injury.
- Subject is male and is 18 years or older.
Exclusion Criteria:
- Subject has been injured less than 1 year.
- The subject is known to be azoospermic.
- The subject has an indwelling urethral Foley catheter.
- Subject is under the age of 18 years.
- Subject has an unstable medical condition including, but not limited to, Crohn's disease, ulcerative colitis, colon cancer or has other conditions deemed to be exclusionary per the Investigator.
- Subject is unable to consent or comprehend the procedures and their implications.
- Subject has a permanent implanted electrical device, i.e., cardiac pacemaker, phrenic nerve stimulator, spinal cord stimulator, etc.
- Any subject for whom the procedure or medication is otherwise contraindicated.
- Subject has hypersensitivity to probenecid.
- Subject has a history of uric acid kidney stones and/or peptic ulcer.
- The subject has had a febrile Urinary Tract Infection (UTI) within the 2 months prior to enrollment.
- The subject is taking methotrexate, aspirin, other salicylates, or anti-inflammatory medicines.
- The subject has a history of Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Full dose group
Participants in this group will receive the full dose of probenecid for a total of 90 days.
|
Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
|
|
Experimental: Half dose group
Participants in this group will receive half the dose of probenecid for a total of 90 days.
|
Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
|
|
Placebo Comparator: Control-placebo group
Participants in this group will receive a placebo dose (No active ingredient) for a total of 90 days.
|
Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in total motile sperm count
Time Frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
The total sperm count will be assessed by calculating semen volume times sperm count times sperm motility percentage.The unit of measurement is in Millions.
|
Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in percentage sperm DNA fragmentation
Time Frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
The percentage of DNA fragmented sperm in specimen
|
Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
|
Change in percentage of sperm viability
Time Frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
The percentage of viable sperm ion specimen
|
Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
|
Change in semen inflammasome markers
Time Frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
Markers will be measured in picogram/milliliter units
|
Baseline, up to 6 months post intervention, up to 6 months post follow up.
|
|
Number of treatment-related adverse events
Time Frame: Up to 6 months post follow up.
|
Treatment-related adverse events will be assessed by the treating physician using Common Terminology Criteria for Adverse Events 4 (CTCAE 4)
|
Up to 6 months post follow up.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Emad Ibrahim, MD, University of Miami
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Genital Diseases, Male
- Male Urogenital Diseases
- Trauma, Nervous System
- Spinal Cord Diseases
- Infertility
- Spinal Cord Injuries
- Infertility, Male
- Gout Suppressants
- Antirheumatic Agents
- Uricosuric Agents
- Probenecid
Other Study ID Numbers
Other Study ID Numbers
- 20230188
- CDMRP-SC220060 (Other Grant/Funding Number: Department of Defense)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.